



SciGen Secures the Rights to Oral-lyn™ A Non-Injectable and Non-Inhaler Recombinant Human Insulin From Generex Biotechnology

2nd April, 2008: SciGen Limited (ASX:SIE) announces that it has entered into a product licensing and distribution agreement pursuant to which SciGen Ltd. (www.scigenltd.com) will procure governmental approvals for the importation, distribution, marketing, and sale of Generex's Oral-lyn™, the Company's proprietary oral insulin spray product, in the People's Republic of China, Hong Kong, and the following additional countries: Indonesia, South Korea, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. Pursuant to the terms of the Agreement, SciGen will seek governmental approvals for the sale of Generex Oral-lyn™ in the territory using SciGen's own recombinant human insulin product. SciGen will supply its recombinant human insulin and Generex will formulate and fill Generex Oral-lyn™ in its appointed manufacturing facility for distribution and marketing in SciGen's assigned territory.

About Generex

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world. For more information, visit the Generex website at www.generex.com.

About SciGen:

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.



SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands.

Further information:

Company – Investor Relations	Company
Ms. Maria Aroyan SciGen Australia +61 2 9485 1800 email: mariaaroyan@scigen.com.au	Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9485 1800 +65 9630 5691 (Mobile)